Venetoclax
Venetoclax is an orally administered small-molecule inhibitor of B-cell lymphoma 2 (Bcl-2), the anti-apoptotic protein malignant cells frequently overexpress to escape programmed death.
Venetoclax is an orally administered small-molecule inhibitor of B-cell lymphoma 2 (Bcl-2), the anti-apoptotic protein malignant cells frequently overexpress to escape programmed death. It is a BH3-mimetic: by occupying the BH3-binding groove of Bcl-2 it displaces the pro-apoptotic effectors held there, restoring mitochondrial outer membrane permeabilization, cytochrome c release and caspase activation involving Caspase-3 (CASP3). Its selectivity is the point of its design — the earlier dual inhibitor navitoclax also blocked BCL-xL, on which circulating platelets depend, and the dose-limiting thrombocytopenia that followed prompted a molecule that spares it. Because many hematologic malignancies are held alive by Bcl-2 alone, the resulting apoptosis is rapid and near-complete, and the tumor lysis it can precipitate is why treatment begins with a weekly dose ramp under hydration and uric-acid-lowering cover rather than at full dose. Resistance typically reflects a shift in dependence to related survival proteins such as MCL1, or mutation of the BH3 groove itself. Metabolism by cytochrome P450 3A4 means strong CYP3A inhibitors require dose adjustment.
In the clinic it is a cornerstone of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) treatment, and is being studied in higher-risk myelodysplastic syndrome (MDS). In CLL it anchors fixed-duration, chemotherapy-free regimens with anti-CD20 antibodies such as obinutuzumab or with BTK inhibitors including ibrutinib and acalabrutinib; because its mechanism runs downstream of the DNA damage response, it retains activity in del(17p)/TP53-disrupted disease that resists chemotherapy. In AML, particularly in older or unfit patients, it is most often paired with hypomethylating agents such as azacitidine, turning a population once offered supportive care alone into one with a standard active regimen, and it is under study with intensive cytarabine-based backbones, in transplant conditioning, and alongside cellular therapies such as CD123-directed CAR-T cells.
Beyond direct killing, venetoclax suppresses oxidative phosphorylation through effects on Mitochondrial respiratory chain complex I, a mechanism implicated in its activity against leukemic stem cells, while its effect on normal lymphocytes and natural killer cells is relevant when combined with immune-based treatments. Newer, more potent Bcl-2 inhibitors such as sonrotoclax are now being evaluated head-to-head against it.
- Upfront venetoclax plus quizartinib with low-dose cytarabine or azacitidine in older unfit patients with acute myeloid leukemia: the phase I/II VEN-A-QUI trial. PMID 43035765
Where the papers sit
32 papers from the last 6 months study venetoclax directly
Study type 9 clinical trials · 7 observational · 7 human data · 5 preclinical · 4 unclassified
Themes 5 themes · 1 paradigm shift
-
AML Venetoclax Sensitivity
AML studies are moving from describing venetoclax activity toward predicting and overcoming resistance. Nucleolin alterations, ROS production, ex vivo drug sensitivity and genetic profiling are proposed markers of response, while impaired OXPHOS through PP2A-B56α stabilization addresses venetoclax-azacitidine resistance. Lipid nanomedicine, novel compounds, γδ T cells and CD123 CAR-T cells extend combination strategies beyond chemotherapy. Early oral CC-486 plus venetoclax data support feasibility, but most evidence remains preclinical or early phase.
10 papers · 31.2%
-
AML Hypomethylating Combinations
Venetoclax plus hypomethylating agents is becoming a central lower-intensity approach for older or unfit AML, with real-world studies testing whether trial benefits persist. Fixed-time treatment and composite remission, survival and MRD outcomes are replacing indefinite exposure as key endpoints. FLT3-directed quizartinib and dual BCL-xL/BCL-2 inhibition with navitoclax are pushing toward molecularly or biologically intensified combinations. Relapsed AML remains less settled, with investigational agents compared against conventional salvage.
7 papers · 21.9%
-
High-Risk Combination Therapy
Venetoclax is being positioned around high-risk treatment transitions: post-transplant maintenance, transplant conditioning, Richter transformation and TP53-altered AML or mantle cell lymphoma. Studies emphasize response rate, survival and MRD to identify patients who benefit from combination therapy. Azacitidine combinations are being refined with genomic predictors, while obinutuzumab ramp-up seeks safer delivery and ibrutinib adds targeted pressure in mantle cell lymphoma. The settings remain clinically diverse, so no single regimen or durable-survival standard has emerged.
7 papers · 21.9%
-
Blood Cancer Treatment Outcomes
Long-term venetoclax use is being judged by durability, MRD kinetics and treatment toxicity across relapsed CLL and other blood cancers. Continuous therapy produces extended follow-up in CLL, while obinutuzumab and zanubrutinib combinations explore deeper remission and retreatment. Febrile neutropenia and drug exposure recur as safety concerns, including in acute leukemia. Evidence remains divided across CLL, mantle cell lymphoma and acute lymphoblastic leukemia rather than defining one disease-specific strategy.
6 papers · 18.8%
-
FLT3-Mutated AML Triplets
FLT3-mutated AML is moving toward triplet treatment with azacitidine, venetoclax and gilteritinib rather than backbone therapy alone. Patient-tailored dosing aims to preserve remission activity while limiting cytopenias, especially thrombocytopenia and neutropenia. Long-term follow-up is testing whether early encouraging responses translate into durable survival. Tolerability and the best sequencing of FLT3 inhibition with venetoclax remain open questions.
2 papers · 6.2%
Venetoclax can potentiate therapeutic immune effector cells rather than merely act directly on malignant cells
Ex vivo venetoclax conditioning of γδ T cells and CAR-γδ T cells in acute myeloid leukemia models 42490148Jul, and venetoclax conditioning of CD123 CAR-T cells against myeloid neoplasms 42277354Jun, instead use venetoclax on the antitumor effector cells rather than on the leukemia alone. Both studies found enhanced immune-cell cytotoxicity and activity against malignant cells, with the γδ T-cell study additionally reporting greater proliferation, reduced exhaustion, and durable xenograft control, while the CD123 CAR-T study found increased killing and cytokine secretion after venetoclax exposure. This reverses the set’s prevailing drug role: venetoclax becomes an ex vivo immunotherapy-conditioning agent whose benefit is mediated partly through strengthening cellular therapy, not simply through direct BCL-2-dependent leukemia-cell killing.
Papers
The 32 papers from the last 6 months that study venetoclax directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
AML Venetoclax Sensitivity (10)
- Photoredox and PIFA-mediated synthesis of N-aryl azacoumestanes: Antileukemic activity and venetoclax synergism in acute myeloid leukemia. Bioorganic chemistry · 15 Oct 2026 PMID 42880119
- Nucleolin Alterations and ROS Production Associate With Sensitivity of AML Cells to Venetoclax. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 26 Sept 2026 PMID 42798295
- Stabilization of the PP2A-B56α complex overcomes venetoclax-azacitidine resistance by impairing OXPHOS in AML. JCI insight · 15 Sept 2026 PMID 42742967
- A dual MYC and GSPT1 protein degrader for MYC-driven hematologic malignancies. Blood · 17 Aug 2026 PMID 42607078
- Bioactive venetoclax-lipid nanomedicine enhances therapeutic efficacy in acute myeloid leukemia. Journal of materials chemistry. B · 30 Jul 2026 PMID 42529898
- A phase 1/1b study of the all-oral regimen CC-486 and venetoclax in acute myeloid leukemia. Blood advances · 24 Jul 2026 PMID 42498285
- Ex vivo pretreatment with venetoclax boosts antileukemic efficacy of therapeutic γδ T cells in AML models. The Journal of clinical investigation · 23 Jul 2026 PMID 42490148
- Oral Regimens for AML Make Strides. Cancer discovery · 27 Jun 2026 PMID 42363683
- Efficacy analysis of CAR-T cells against CD123-positive malignant tumors and exploration of the feasibility of combination therapy with venetoclax. Annals of hematology · 11 Jun 2026 PMID 42277354
- Integrating ex vivo drug sensitivity and genetic mutation analysis improves prediction of chemotherapy response in acute myeloid leukemia. Functional & integrative genomics · 28 May 2026 PMID 42209825
AML Hypomethylating Combinations (7)
- Upfront venetoclax plus quizartinib with low-dose cytarabine or azacitidine in older unfit patients with acute myeloid leukemia: the phase I/II VEN-A-QUI trial. Journal of hematology & oncology · 15 Nov 2026 PMID 43035765
- Hypomethylating agents with venetoclax for newly diagnosed acute myeloid leukemia in patients 65 and older in The Netherlands - A nationwide study of drug usage and treatment outcomes. European journal of cancer (Oxford, England : 1990) · 27 Aug 2026 PMID 42659837
- Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial. British journal of haematology · 17 Aug 2026 PMID 42608172
- Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study. Leukemia & lymphoma · 29 Jul 2026 PMID 42525505
- Investigational Clinical Trial Agents versus Conventional Second Salvage Therapies in Patients with Relapsed/Refractory Acute Myeloid Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research · 22 Jun 2026 PMID 42329225
- Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine. Clinical cancer research : an official journal of the American Association for Cancer Research · 26 May 2026 PMID 42189880
- Fixed-time treatment of elderly patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) using hypomethylating agents and venetoclax - a case series. Annals of hematology · 22 May 2026 PMID 42171770
High-Risk Combination Therapy (7)
- Real-World Survival Outcomes of Venetoclax Combination Therapies in Acute Myeloid Leukemia: Impact of Minimal Residual Disease Status and Antifungal Prophylaxis. Hematological oncology · 13 Oct 2026 PMID 42867841
- Genomic and clinical determinants of response to Azacitidine plus venetoclax in acute myeloid leukemia: Results from the HM-SCREEN-Japan 02 study. PloS one · 1 Oct 2026 PMID 42821569
- Venetoclax in Combination With Chemo-Immunotherapy in Richter Transformation: A Real-Life Experience. Hematological oncology · 17 Aug 2026 PMID 42607055
- Defining a Therapeutic Window for Venetoclax in Post-Transplant Maintenance Therapy for High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes. Hematological oncology · 6 Aug 2026 PMID 42561008
- First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations. Blood · 16 Jul 2026 PMID 42462092
- Safe Accelerated Venetoclax Escalation: a phase 1b study of obinutuzumab plus venetoclax with daily ramp-up in CLL. Blood advances · 23 Jun 2026 PMID 42335220
- Integration of venetoclax into a fludarabine and melphalan conditioning regimen in patients aged 50 years and older with acute myeloid leukemia and myelodysplastic syndrome: Results from a phase 2 clinical trial. Cancer · 20 May 2026 PMID 42159161
Blood Cancer Treatment Outcomes (6)
- Association between venetoclax concentration and febrile neutropenia in acute leukemia: a retrospective analysis. European journal of clinical pharmacology · 1 Aug 2026 PMID 42541584
- Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia. Blood advances · 24 Jul 2026 PMID 42498281
- Zanubrutinib, obinutuzumab, and venetoclax in CLL: long-term follow up, MRD kinetics, retreatment, T-cell profiling, and PKs. Blood advances · 30 Jun 2026 PMID 42379251
- Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia. Blood · 21 May 2026 PMID 42166560
- Chromosome 5q deletion drives evolution of aneuploidy in myeloid neoplasms with complex karyotype. Blood · 21 May 2026 PMID 42166356
- First BCL-2 Inhibitor Approved for Mantle Cell Lymphoma. Cancer discovery · 21 May 2026 PMID 42166034
FLT3-Mutated AML Triplets (2)
- Patient-tailored azacitidine, venetoclax and gilteritinib triplet therapy appear to improve tolerability while preserving encouraging clinical outcomes in FLT3-mutated relapsed/refractory AML. Annals of hematology · 23 Oct 2026 PMID 42909668
- Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML. Blood advances · 27 May 2026 PMID 42200455
By study type
Clinical trials (9)
- Upfront venetoclax plus quizartinib with low-dose cytarabine or azacitidine in older unfit patients with acute myeloid leukemia: the phase I/II VEN-A-QUI trial. Journal of hematology & oncology · 15 Nov 2026 PMID 43035765
- A phase 1/1b study of the all-oral regimen CC-486 and venetoclax in acute myeloid leukemia. Blood advances · 24 Jul 2026 PMID 42498285
- First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations. Blood · 16 Jul 2026 PMID 42462092
- Zanubrutinib, obinutuzumab, and venetoclax in CLL: long-term follow up, MRD kinetics, retreatment, T-cell profiling, and PKs. Blood advances · 30 Jun 2026 PMID 42379251
- Safe Accelerated Venetoclax Escalation: a phase 1b study of obinutuzumab plus venetoclax with daily ramp-up in CLL. Blood advances · 23 Jun 2026 PMID 42335220
- Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML. Blood advances · 27 May 2026 PMID 42200455
- Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine. Clinical cancer research : an official journal of the American Association for Cancer Research · 26 May 2026 PMID 42189880
- Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia. Blood · 21 May 2026 PMID 42166560
- Integration of venetoclax into a fludarabine and melphalan conditioning regimen in patients aged 50 years and older with acute myeloid leukemia and myelodysplastic syndrome: Results from a phase 2 clinical trial. Cancer · 20 May 2026 PMID 42159161
Observational studies and case reports (7)
- Patient-tailored azacitidine, venetoclax and gilteritinib triplet therapy appear to improve tolerability while preserving encouraging clinical outcomes in FLT3-mutated relapsed/refractory AML. Annals of hematology · 23 Oct 2026 PMID 42909668
- Hypomethylating agents with venetoclax for newly diagnosed acute myeloid leukemia in patients 65 and older in The Netherlands - A nationwide study of drug usage and treatment outcomes. European journal of cancer (Oxford, England : 1990) · 27 Aug 2026 PMID 42659837
- Venetoclax in Combination With Chemo-Immunotherapy in Richter Transformation: A Real-Life Experience. Hematological oncology · 17 Aug 2026 PMID 42607055
- Defining a Therapeutic Window for Venetoclax in Post-Transplant Maintenance Therapy for High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes. Hematological oncology · 6 Aug 2026 PMID 42561008
- Association between venetoclax concentration and febrile neutropenia in acute leukemia: a retrospective analysis. European journal of clinical pharmacology · 1 Aug 2026 PMID 42541584
- Investigational Clinical Trial Agents versus Conventional Second Salvage Therapies in Patients with Relapsed/Refractory Acute Myeloid Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research · 22 Jun 2026 PMID 42329225
- Fixed-time treatment of elderly patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) using hypomethylating agents and venetoclax - a case series. Annals of hematology · 22 May 2026 PMID 42171770
Human data, design not indexed (7)
- Real-World Survival Outcomes of Venetoclax Combination Therapies in Acute Myeloid Leukemia: Impact of Minimal Residual Disease Status and Antifungal Prophylaxis. Hematological oncology · 13 Oct 2026 PMID 42867841
- Genomic and clinical determinants of response to Azacitidine plus venetoclax in acute myeloid leukemia: Results from the HM-SCREEN-Japan 02 study. PloS one · 1 Oct 2026 PMID 42821569
- Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia. Blood advances · 24 Jul 2026 PMID 42498281
- Oral Regimens for AML Make Strides. Cancer discovery · 27 Jun 2026 PMID 42363683
- Integrating ex vivo drug sensitivity and genetic mutation analysis improves prediction of chemotherapy response in acute myeloid leukemia. Functional & integrative genomics · 28 May 2026 PMID 42209825
- Chromosome 5q deletion drives evolution of aneuploidy in myeloid neoplasms with complex karyotype. Blood · 21 May 2026 PMID 42166356
- First BCL-2 Inhibitor Approved for Mantle Cell Lymphoma. Cancer discovery · 21 May 2026 PMID 42166034
Preclinical: animal, cell and lab studies (5)
- Photoredox and PIFA-mediated synthesis of N-aryl azacoumestanes: Antileukemic activity and venetoclax synergism in acute myeloid leukemia. Bioorganic chemistry · 15 Oct 2026 PMID 42880119
- Nucleolin Alterations and ROS Production Associate With Sensitivity of AML Cells to Venetoclax. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 26 Sept 2026 PMID 42798295
- A dual MYC and GSPT1 protein degrader for MYC-driven hematologic malignancies. Blood · 17 Aug 2026 PMID 42607078
- Bioactive venetoclax-lipid nanomedicine enhances therapeutic efficacy in acute myeloid leukemia. Journal of materials chemistry. B · 30 Jul 2026 PMID 42529898
- Ex vivo pretreatment with venetoclax boosts antileukemic efficacy of therapeutic γδ T cells in AML models. The Journal of clinical investigation · 23 Jul 2026 PMID 42490148
Unclassified: not yet indexed with MeSH (4)
- Stabilization of the PP2A-B56α complex overcomes venetoclax-azacitidine resistance by impairing OXPHOS in AML. JCI insight · 15 Sept 2026 PMID 42742967
- Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial. British journal of haematology · 17 Aug 2026 PMID 42608172
- Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study. Leukemia & lymphoma · 29 Jul 2026 PMID 42525505
- Efficacy analysis of CAR-T cells against CD123-positive malignant tumors and exploration of the feasibility of combination therapy with venetoclax. Annals of hematology · 11 Jun 2026 PMID 42277354
Written from 32 PubMed abstracts, each one listed by PMID above. Published: 2026-07-02. Last written: 2026-09-17 by GPT. Corrections: 2026-08-08 by GPT. Reviewed by a human editor on 2026-07-24. Drafted by language models from published abstracts; not medical advice.